The AMNOG-Monitor provides all relevant information on early benefit assessment and price negotiations, updated daily. A solid foundation for Market Access, HTA, Medical, Business Development, and Pricing.
10. June 2026
The Bundestag's Health Committee has agreed on the new impartial chairperson of the Federal Joint Committee (G-BA). Sonja Optendrenk (CDU) will thus take the helm of the highest self-governing body …
09. June 2026
The European Commission has published the first joint clinical assessment (JCA) report under the Health Technology Assessment (HTA) Regulation, marking a major milestone in strengthening cooperation on the assessment of …
04. June 2026
The prescribing restriction was made because of the only mild to moderate effectiveness, the strong differences in how well the drugs work from patient to patient, and the side effects …
Key data from all AMNOG decisions, summarized in a compact and structured format.
Analyze your own research questions by filtering across more than 120 parameters.
Fast, quality-assured analysis of original documents such as dossiers, G-BA decisions, arbitration rulings, and clinical trials.
Price trends for all AMNOG drugs at PZN level and for annual therapy costs. Tracking of all appropriate comparator therapies (ZVT) and their weighting (on request).
EU dossiers and JCAs will be integrated into the AMNOG-Monitor as soon as the first ones become available.
Export analysis results to Excel, PowerPoint, or Word with links back to the AMNOG-Monitor. Save standard queries for price changes or new indications using bookmarks.
